Safety and efficacy of switching to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with renal impairment: week 48 results from a phase 2 open label study

Autor:	Janssen, Harry, Lampertico, Pietro, Chen, Chi-Yi, Heo, Jeong, Fournier, Claire, Ahn, Sang Hoon, Tsang, Tak Yin Owen, Coffin, Carla, Reggiani, Giulio Marchesini, Huang, Yi-Hsiang, Hui, Aric Josun, Elkhashab, Magdy, Chen, Chien-Hung, Jafri, Syed Mohammed Raza, Tan, Susanna, Mo, Shuyuan, Suri, Vithika, Flaherty, John F., Gaggar, Anuj, Subramanian, Mani, Agarwal, Kosh, Wan-Long Chuang, Gane, Edward, Lim, Young-Suk
Rok vydání:	2020
Předmět:	Hepatology
Zdroj:	Web of Science
ISSN:	0168-8278
DOI:	10.1016/s0168-8278(20)32176-0
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::199cc7db6aaa69769f59e4318070e48d https://doi.org/10.1016/s0168-8278(20)32176-0 Zobrazit plný text záznamu Full Text from ScienceDirect